An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis

Atherosclerosis is the underlying cause of myocardial infarction and ischemic stroke. It is a lipid-triggered and cytokine/chemokine-driven arterial inflammatory condition. We identify D-dopachrome tautomerase/macrophage migration-inhibitory factor-2 (MIF-2), a paralog of the cytokine MIF, as an atypical chemokine promoting both atherosclerosis and hepatic lipid accumulation. In hyperlipidemic Apoe<sup>-/-</sup> mice, Mif-2-deficiency and pharmacological MIF-2-blockade protect against lesion formation and vascular inflammation in early and advanced atherogenesis. MIF-2 promotes leukocyte migration, endothelial arrest, and foam-cell formation, and we identify CXCR4 as a receptor for MIF-2. Mif-2-deficiency in Apoe<sup>-/-</sup> mice leads to decreased plasma lipid levels and suppressed hepatic lipid accumulation, characterized by reductions in lipogenesis-related pathways, tri-/diacylglycerides, and cholesterol-esters, as revealed by hepatic transcriptomics/lipidomics. Hepatocyte cultures and FLIM-FRET-microscopy suggest that MIF-2 activates SREBP-driven lipogenic genes, mechanistically involving MIF-2-inducible CD74/CXCR4 complexes and PI3K/AKT but not AMPK signaling. MIF-2 is upregulated in unstable carotid plaques from atherosclerotic patients and its plasma concentration correlates with disease severity in patients with coronary artery disease. These findings establish MIF-2 as an atypical chemokine linking vascular inflammation to metabolic dysfunction in atherosclerosis.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-03-07
DOI
https://doi.org/10.1038/s41467-025-57540-z
Citations
12
Primary Topic
Macrophage Migration Inhibitory Factor
Type
article
Field-Weighted Citation Impact
9.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis

W. Kempf, Simon Ebert, Alexander Bartelt, Nadja Sachs et al.
12 citations
Nature Communications
Macrophage Migration Inhibitory Factor
9.57
article

An atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis

W. Kempf, Simon Ebert, Alexander Bartelt, Nadja Sachs, Naomi E. Kramer, Richard Bucala, Dzmitry Sinitski, Aphrodite Kapurniotu, Lars Mäegdefessel, Simona Gerra, Jonas Wagner, Christos K. Kontos, Priscila Bourilhon, Hao Ji, Marlies Zarwel, Omar El Bounkari, Markus Brandhofer, Jelena Milić, Remco T. A. Megens, Dominik Rath, Denise Messerer, Nienke Willemsen, Yvonne Jansen, Yvonne Döring, Elina Bugar, Chunfang Zan, Adrian Hoffmann, Mark Haid, Tobias Harm, Meinrad Gawaz, Jürgen Bernhagen, Fabien Riols, Özgün Gökçe, Christian Weber, Bishan Yang, Christian Schulz, Maida Avdic
article en
12 citations

Abstract

Atherosclerosis is the underlying cause of myocardial infarction and ischemic stroke. It is a lipid-triggered and cytokine/chemokine-driven arterial inflammatory condition. We identify D-dopachrome tautomerase/macrophage migration-inhibitory factor-2 (MIF-2), a paralog of the cytokine MIF, as an atypical chemokine promoting both atherosclerosis and hepatic lipid accumulation. In hyperlipidemic Apoe<sup>-/-</sup> mice, Mif-2-deficiency and pharmacological MIF-2-blockade protect against lesion formation and vascular inflammation in early and advanced atherogenesis. MIF-2 promotes leukocyte migration, endothelial arrest, and foam-cell formation, and we identify CXCR4 as a receptor for MIF-2. Mif-2-deficiency in Apoe<sup>-/-</sup> mice leads to decreased plasma lipid levels and suppressed hepatic lipid accumulation, characterized by reductions in lipogenesis-related pathways, tri-/diacylglycerides, and cholesterol-esters, as revealed by hepatic transcriptomics/lipidomics. Hepatocyte cultures and FLIM-FRET-microscopy suggest that MIF-2 activates SREBP-driven lipogenic genes, mechanistically involving MIF-2-inducible CD74/CXCR4 complexes and PI3K/AKT but not AMPK signaling. MIF-2 is upregulated in unstable carotid plaques from atherosclerotic patients and its plasma concentration correlates with disease severity in patients with coronary artery disease. These findings establish MIF-2 as an atypical chemokine linking vascular inflammation to metabolic dysfunction in atherosclerosis.

Nature CommunicationsVol. 16(1)
University of Bern (CH), University of Mannheim (DE), Heidelberg University (DE), University Hospital Bonn (DE), University Hospital of Bern (CH), German Center for Neurodegenerative Diseases (DE), University Hospital Heidelberg (DE), Helmholtz Zentrum München (DE), LMU Klinikum (DE), Yale University (US), Maastricht University (NL), Munich Cluster for Systems Neurology (DE), University Children's Hospital Tübingen (DE), German Centre for Cardiovascular Research (DE), University Medical Centre Mannheim (DE), German Center for Diabetes Research (DE), Technical University of Munich (DE), University of Tübingen (DE), Ludwig-Maximilians-Universität München (DE)
Deutsches Zentrum für Herz-Kreislaufforschung, Deutsche Forschungsgemeinschaft, China Scholarship Council, Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung., National Institutes of Health
Good health and well-being
Openalex Percentile: Top 2%
Macrophage Migration Inhibitory Factor
9.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.